世界の放射免疫療法産業調査レポート、成長動向と競争分析 2023-2029Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2023-2029 COVID-19のパンデミックにより、世界の放射免疫療法の市場規模は2022年に1億4283万米ドルであり、2023年から2029年の予測期間中のCAGRは17.43%で、2029年までに4億4779万米ドルに再調整されると予測されている。... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリーCOVID-19のパンデミックにより、世界の放射免疫療法の市場規模は2022年に1億4283万米ドルであり、2023年から2029年の予測期間中のCAGRは17.43%で、2029年までに4億4779万米ドルに再調整されると予測されている。ラジオ免疫療法の世界の主要企業には、バイエル、ノバルティス、ランテウス、オーロビンド・ファーマ、ムンディファーマ、中国アイソトープ・放射線、キュリウム・ファーマシューティカルズなどが含まれる。2022年には、世界の上位5社が売上高で約99.25%のシェアを占めている。 米国のラジオ免疫療法市場規模は2022年に5億462万米ドルであり、中国規模は2372万米ドルであった。米国の割合は2022年に48.39%であったが、中国の割合は2.27%であり、中国のシェアは2029年に1.44%に達し、分析期間を通じて20.26%のCAGRをたどると予測されている。欧州の放射線免疫療法に関しては、ドイツは2029年までに3億2700万米ドルに達すると予測されている。 この調査レポートは、メーカー、利害関係者、意思決定者、その他の市場参加者が、世界の放射線免疫療法市場の成長に影響を与えるあらゆる要因に精通するのに役立つ非常に有用な資料です。本レポートを執筆したアナリストは、世界のRadioimmunotherapy市場のトップ企業が採用する主要戦略を綿密に調査しました。また、SWOTなどの市場分析も行い、世界のRadioimmunotherapy市場の重要な側面について明確かつ深い理解を提供します。本レポートの読者は、世界のRadioimmunotherapy市場の現在および将来の動向と、それらが予測期間中の市場成長にどのような影響を与えるかについて知ることができます。 企業別 バイエル ノバルティス ランテウス オーロビンド・ファーマ ムンディファーマ 中国アイソトープ・放射線 キュリウム・ファーマシューティカルズ パイプライン ギリアド・サイエンシズ クラリティ・ファーマシューティカルズ キュラサイト ノルディック・ナノベクター フィロゲン ラジオメディックス テリックス・ファーマシューティカルズ オラノメッド アクティニウム・ファーマシューティカルズ Y-mAbsセラピューティクス フュージョン・ファーマシューティカルズ タイプ別セグメント ベータ線放出 標的α療法 用途別セグメント 非ホジキンリンパ腫(NHL) 固形がん 地域別 北米 米国 カナダ アジア太平洋 中国 日本 韓国 インド 東南アジア ヨーロッパ ドイツ フランス 英国 イタリア ロシア ラテンアメリカ メキシコ ブラジル 中東・アフリカ 中東 アフリカ 各章の概要 第1章:報告書のスコープ、異なる市場セグメント(製品タイプ、アプリケーションなど)のエグゼクティブサマリー、各市場セグメントの市場規模、将来の発展の可能性などを紹介します。 第2章:世界および地域レベルでの放射線免疫療法の収益。 第3章:ラジオ免疫療法企業鈥の競争環境、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。 第4章:各種市場セグメントをタイプ別に分析し、各市場セグメントの収益、発展の可能性を網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけるのに役立つ。 第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、発展の可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第6章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の収益。 第7章:ヨーロッパ:タイプ別、用途別、国別、セグメント別収益 第8章:アジア太平洋地域:タイプ別、用途別、地域別、セグメント別収益 第9章:ラテンアメリカ:タイプ別、用途別、国別、セグメント別収益。 第10章: 中東・アフリカ: タイプ別、用途別、国別、セグメント別収益。 第11章:主要企業のプロファイルを提供し、製品の説明や仕様、ラジオイムノセラピーの収益、売上総利益率、事業戦略など、市場の主要企業の基本的な状況を詳細に紹介します。 第12章:市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を紹介します。 第13章 調査結果と結論 目次1 Report Overview 11.1 Study Scope 1 1.2 Market Analysis by Type 1 1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1 1.2.2 Targeted Alpha Therapy 3 1.2.3 Beta-emitting 4 1.3 Market by Application 7 1.3.1 Global Radioimmunotherapy Market Growth by Application: 2018 VS 2022 VS 2029 7 1.3.2 Non Hodgkin Lymphoma (NHL) 9 1.3.3 Solid Tumor 10 1.4 Assumptions and Limitations 12 1.5 Study Objectives 13 1.6 Years Considered 14 2 Market Perspective 15 2.1 Global Radioimmunotherapy Market Size 2018-2029 15 2.2 Radioimmunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029 16 2.3 Global Radioimmunotherapy Market Size by Region (2018-2023) 18 2.4 Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) 20 2.5 Global Top 10 Radioimmunotherapy Countries Ranking by Market Size 21 3 Radioimmunotherapy Competition by Company 23 3.1 Global Radioimmunotherapy Revenue by Players 23 3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2023) 23 3.1.2 Global Radioimmunotherapy Market Share by Players (2018-2023) 24 3.2 Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) 25 3.3 Company Covered: Ranking by Radioimmunotherapy Revenue 25 3.4 Global Radioimmunotherapy Market Concentration Ratio 26 3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI) 26 3.4.2 Global Top 5 Companies by Radioimmunotherapy Revenue in 2022 27 3.5 Global Key Players of Radioimmunotherapy Head office and Area Served 27 3.6 Global Key Players of Radioimmunotherapy, Product and Application 28 3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28 3.8 Mergers & Acquisitions, Expansion Plans 29 4 Global Radioimmunotherapy Breakdown Data by Type 30 4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2023) 30 4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) 31 5 Global Radioimmunotherapy Breakdown Data by Application 32 5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2023) 32 5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) 33 6 North America 34 6.1 North America Radioimmunotherapy Revenue by Company (2021-2023) 34 6.2 North America Radioimmunotherapy Revenue by Type (2018-2029) 35 6.3 North America Radioimmunotherapy Revenue by Application (2018-2029) 36 6.4 North America Radioimmunotherapy Revenue by Country (2018-2029) 37 6.4.1 United States 38 6.4.2 Canada 39 7 Europe 40 7.1 Europe Radioimmunotherapy Revenue by Company (2021-2023) 40 7.2 Europe Radioimmunotherapy Revenue by Type (2018-2029) 41 7.3 Europe Radioimmunotherapy Revenue by Application (2018-2029) 42 7.4 Europe Radioimmunotherapy Revenue by Country (2018-2029) 43 7.4.1 Germany 45 7.4.2 France 45 7.4.3 U.K. 46 7.4.4 Italy 46 7.4.5 Russia 47 8 Asia Pacific 48 8.1 Asia Pacific Radioimmunotherapy Revenue by Company (2021-2023) 48 8.2 Asia Pacific Radioimmunotherapy Revenue by Type (2018-2029) 49 8.3 Asia Pacific Radioimmunotherapy Revenue by Application (2018-2029) 50 8.4 Asia Pacific Radioimmunotherapy Revenue by Region (2018-2029) 51 8.4.1 China 53 8.4.2 Japan 53 8.4.3 South Korea 54 8.4.4 India 54 8.4.5 Southeast Asia 55 9 Latin America 56 9.1 Latin America Radioimmunotherapy Revenue by Company (2021-2023) 56 9.2 Latin America Radioimmunotherapy Revenue by Type (2018-2029) 57 9.3 Latin America Radioimmunotherapy Revenue by Application (2018-2029) 58 9.4 Latin America Radioimmunotherapy Revenue by Country (2018-2029) 58 9.4.1 Mexico 60 9.4.2 Brazil 60 10 Middle East and Africa 61 10.1 Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2023) 61 10.2 Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2029) 62 10.3 Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2029) 63 10.4 Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2029) 63 10.4.1 Middle East 65 10.4.2 Africa 65 11 Company Profiles 66 11.1 Bayer 66 11.1.1 Bayer Company Details 66 11.1.2 Bayer Business Overview 66 11.1.3 Bayer Radioimmunotherapy Products and Services 67 11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2023) 68 11.1.5 Bayer Radioimmunotherapy SWOT Analysis 68 11.1.6 Bayer Business Strategy 69 11.2 Novartis 69 11.2.1 Novartis Company Details 70 11.2.2 Novartis Business Overview 70 11.2.3 Novartis Radioimmunotherapy Products and Services 71 11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2023) 72 11.2.5 Novartis Radioimmunotherapy SWOT Analysis 72 11.2.6 Novartis Business Strategy 73 11.3 Lantheus 73 11.3.1 Lantheus Company Details 74 11.3.2 Lantheus Business Overview 74 11.3.3 Lantheus Radioimmunotherapy Products and Services 75 11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2023) 75 11.3.5 Lantheus Radioimmunotherapy SWOT Analysis 76 11.3.6 Lantheus Business Strategy 77 11.4 Aurobindo Pharma 77 11.4.1 Aurobindo Pharma Company Details 78 11.4.2 Aurobindo Pharma Business Overview 78 11.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 79 11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2023) 79 11.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80 11.4.6 Aurobindo Pharma Business Strategy 81 11.5 Mundipharma 81 11.5.1 Mundipharma Company Details 81 11.5.2 Mundipharma Business Overview 82 11.5.3 Mundipharma Radioimmunotherapy Products and Services 83 11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2023) 83 11.5.5 Mundipharma Business Strategy 84 11.6 China Isotope & Radiation 84 11.6.1 China Isotope & Radiation Company Details 84 11.6.2 China Isotope & Radiation Business Overview 85 11.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 85 11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2023) 86 11.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86 11.6.6 China Isotope & Radiation Business Strategy 87 11.7 Curium Pharmaceuticals 88 11.7.1 Curium Pharmaceuticals Company Details 88 11.7.2 Curium Pharmaceuticals Business Overview 88 11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 89 11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2023) 89 11.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90 11.7.6 Curium Pharmaceuticals Business Strategy 91 11.8 Gilead Sciences 91 11.8.1 Gilead Sciences Company Details 92 11.8.2 Gilead Sciences Business Overview 92 11.8.3 Gilead Sciences Radioimmunotherapy Products and Services 93 11.8.4 Gilead Sciences Business Strategy 93 11.9 Clarity Pharmaceuticals 94 11.9.1 Clarity Pharmaceuticals Company Details 94 11.9.2 Clarity Pharmaceuticals Business Overview 94 11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95 11.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95 11.9.5 Clarity Pharmaceuticals Business Strategy 96 11.10 Curasight 96 11.10.1 Curasight Company Details 96 11.10.2 Curasight Business Overview 97 11.10.3 Curasight Radioimmunotherapy Products and Services 97 11.10.4 Curasight Radioimmunotherapy SWOT Analysis 98 11.10.5 Curasight Business Strategy 98 11.11 Nordic Nanovector 99 11.11.1 Nordic Nanovector Company Details 99 11.11.2 Nordic Nanovector Business Overview 100 11.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 100 11.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 100 11.11.5 Nordic Nanovector Business Strategy 101 11.12 Philogen 102 11.12.1 Philogen Company Details 102 11.12.2 Philogen Business Overview 102 11.12.3 Philogen Radioimmunotherapy Products and Services 103 11.12.4 Philogen Radioimmunotherapy SWOT Analysis 103 11.12.5 Philogen Business Strategy 104 11.13 RadioMedix 104 11.13.1 RadioMedix Company Details 104 11.13.2 RadioMedix Business Overview 105 11.13.3 RadioMedix Radioimmunotherapy Products and Services 105 11.13.4 RadioMedix Business Strategy 105 11.14 Telix Pharmaceuticals 106 11.14.1 Telix Pharmaceuticals Company Details 106 11.14.2 Telix Pharmaceuticals Business Overview 107 11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 107 11.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108 11.14.5 Telix Pharmaceuticals Business Strategy 108 11.15 Orano Med 109 11.15.1 Orano Med Company Details 109 11.15.2 Orano Med Business Overview 110 11.15.3 Orano Med Radioimmunotherapy Products and Services 110 11.15.4 Orano Med Radioimmunotherapy SWOT Analysis 110 11.15.5 Orano Med Business Strategy 111 11.16 Actinium Pharmaceuticals 111 11.16.1 Actinium Pharmaceuticals Company Details 111 11.16.2 Actinium Pharmaceuticals Business Overview 112 11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112 11.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113 11.16.5 Actinium Pharmaceuticals Business Strategy 113 11.17 Y-mAbs Therapeutics 114 11.17.1 Y-mAbs Therapeutics Company Details 114 11.17.2 Y-mAbs Therapeutics Business Overview 114 11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115 11.17.4 Y-mAbs Therapeutics Business Strategy 116 11.18 Fusion Pharmaceuticals 116 11.18.1 Fusion Pharmaceuticals Company Details 116 11.18.2 Fusion Pharmaceuticals Business Overview 117 11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117 11.18.4 Fusion Pharmaceuticals Business Strategy 118 12 Radioimmunotherapy Market Dynamics 120 12.1 Radioimmunotherapy Industry Trends 120 12.2 Radioimmunotherapy Market Drivers 121 12.3 Radioimmunotherapy Market Challenges 122 12.4 Radioimmunotherapy Market Restraints 123 13 Research Findings and Conclusion 124 14 Appendix 126 14.1 Research Methodology 126 14.1.1 Methodology/Research Approach 126 14.1.2 Data Source 129 14.2 Author Details 132 14.3 Disclaimer 135
SummaryDue to the COVID-19 pandemic, the global Radioimmunotherapy market size was US$ 1042.83 million in 2022 and is forecast to a readjusted size of US$ 4479 million by 2029 with a CAGR of 17.43% during the forecast period 2023-2029. Table of Contents1 Report Overview 11.1 Study Scope 1 1.2 Market Analysis by Type 1 1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1 1.2.2 Targeted Alpha Therapy 3 1.2.3 Beta-emitting 4 1.3 Market by Application 7 1.3.1 Global Radioimmunotherapy Market Growth by Application: 2018 VS 2022 VS 2029 7 1.3.2 Non Hodgkin Lymphoma (NHL) 9 1.3.3 Solid Tumor 10 1.4 Assumptions and Limitations 12 1.5 Study Objectives 13 1.6 Years Considered 14 2 Market Perspective 15 2.1 Global Radioimmunotherapy Market Size 2018-2029 15 2.2 Radioimmunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029 16 2.3 Global Radioimmunotherapy Market Size by Region (2018-2023) 18 2.4 Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) 20 2.5 Global Top 10 Radioimmunotherapy Countries Ranking by Market Size 21 3 Radioimmunotherapy Competition by Company 23 3.1 Global Radioimmunotherapy Revenue by Players 23 3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2023) 23 3.1.2 Global Radioimmunotherapy Market Share by Players (2018-2023) 24 3.2 Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) 25 3.3 Company Covered: Ranking by Radioimmunotherapy Revenue 25 3.4 Global Radioimmunotherapy Market Concentration Ratio 26 3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI) 26 3.4.2 Global Top 5 Companies by Radioimmunotherapy Revenue in 2022 27 3.5 Global Key Players of Radioimmunotherapy Head office and Area Served 27 3.6 Global Key Players of Radioimmunotherapy, Product and Application 28 3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28 3.8 Mergers & Acquisitions, Expansion Plans 29 4 Global Radioimmunotherapy Breakdown Data by Type 30 4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2023) 30 4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) 31 5 Global Radioimmunotherapy Breakdown Data by Application 32 5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2023) 32 5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) 33 6 North America 34 6.1 North America Radioimmunotherapy Revenue by Company (2021-2023) 34 6.2 North America Radioimmunotherapy Revenue by Type (2018-2029) 35 6.3 North America Radioimmunotherapy Revenue by Application (2018-2029) 36 6.4 North America Radioimmunotherapy Revenue by Country (2018-2029) 37 6.4.1 United States 38 6.4.2 Canada 39 7 Europe 40 7.1 Europe Radioimmunotherapy Revenue by Company (2021-2023) 40 7.2 Europe Radioimmunotherapy Revenue by Type (2018-2029) 41 7.3 Europe Radioimmunotherapy Revenue by Application (2018-2029) 42 7.4 Europe Radioimmunotherapy Revenue by Country (2018-2029) 43 7.4.1 Germany 45 7.4.2 France 45 7.4.3 U.K. 46 7.4.4 Italy 46 7.4.5 Russia 47 8 Asia Pacific 48 8.1 Asia Pacific Radioimmunotherapy Revenue by Company (2021-2023) 48 8.2 Asia Pacific Radioimmunotherapy Revenue by Type (2018-2029) 49 8.3 Asia Pacific Radioimmunotherapy Revenue by Application (2018-2029) 50 8.4 Asia Pacific Radioimmunotherapy Revenue by Region (2018-2029) 51 8.4.1 China 53 8.4.2 Japan 53 8.4.3 South Korea 54 8.4.4 India 54 8.4.5 Southeast Asia 55 9 Latin America 56 9.1 Latin America Radioimmunotherapy Revenue by Company (2021-2023) 56 9.2 Latin America Radioimmunotherapy Revenue by Type (2018-2029) 57 9.3 Latin America Radioimmunotherapy Revenue by Application (2018-2029) 58 9.4 Latin America Radioimmunotherapy Revenue by Country (2018-2029) 58 9.4.1 Mexico 60 9.4.2 Brazil 60 10 Middle East and Africa 61 10.1 Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2023) 61 10.2 Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2029) 62 10.3 Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2029) 63 10.4 Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2029) 63 10.4.1 Middle East 65 10.4.2 Africa 65 11 Company Profiles 66 11.1 Bayer 66 11.1.1 Bayer Company Details 66 11.1.2 Bayer Business Overview 66 11.1.3 Bayer Radioimmunotherapy Products and Services 67 11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2023) 68 11.1.5 Bayer Radioimmunotherapy SWOT Analysis 68 11.1.6 Bayer Business Strategy 69 11.2 Novartis 69 11.2.1 Novartis Company Details 70 11.2.2 Novartis Business Overview 70 11.2.3 Novartis Radioimmunotherapy Products and Services 71 11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2023) 72 11.2.5 Novartis Radioimmunotherapy SWOT Analysis 72 11.2.6 Novartis Business Strategy 73 11.3 Lantheus 73 11.3.1 Lantheus Company Details 74 11.3.2 Lantheus Business Overview 74 11.3.3 Lantheus Radioimmunotherapy Products and Services 75 11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2023) 75 11.3.5 Lantheus Radioimmunotherapy SWOT Analysis 76 11.3.6 Lantheus Business Strategy 77 11.4 Aurobindo Pharma 77 11.4.1 Aurobindo Pharma Company Details 78 11.4.2 Aurobindo Pharma Business Overview 78 11.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 79 11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2023) 79 11.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80 11.4.6 Aurobindo Pharma Business Strategy 81 11.5 Mundipharma 81 11.5.1 Mundipharma Company Details 81 11.5.2 Mundipharma Business Overview 82 11.5.3 Mundipharma Radioimmunotherapy Products and Services 83 11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2023) 83 11.5.5 Mundipharma Business Strategy 84 11.6 China Isotope & Radiation 84 11.6.1 China Isotope & Radiation Company Details 84 11.6.2 China Isotope & Radiation Business Overview 85 11.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 85 11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2023) 86 11.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86 11.6.6 China Isotope & Radiation Business Strategy 87 11.7 Curium Pharmaceuticals 88 11.7.1 Curium Pharmaceuticals Company Details 88 11.7.2 Curium Pharmaceuticals Business Overview 88 11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 89 11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2023) 89 11.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90 11.7.6 Curium Pharmaceuticals Business Strategy 91 11.8 Gilead Sciences 91 11.8.1 Gilead Sciences Company Details 92 11.8.2 Gilead Sciences Business Overview 92 11.8.3 Gilead Sciences Radioimmunotherapy Products and Services 93 11.8.4 Gilead Sciences Business Strategy 93 11.9 Clarity Pharmaceuticals 94 11.9.1 Clarity Pharmaceuticals Company Details 94 11.9.2 Clarity Pharmaceuticals Business Overview 94 11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95 11.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95 11.9.5 Clarity Pharmaceuticals Business Strategy 96 11.10 Curasight 96 11.10.1 Curasight Company Details 96 11.10.2 Curasight Business Overview 97 11.10.3 Curasight Radioimmunotherapy Products and Services 97 11.10.4 Curasight Radioimmunotherapy SWOT Analysis 98 11.10.5 Curasight Business Strategy 98 11.11 Nordic Nanovector 99 11.11.1 Nordic Nanovector Company Details 99 11.11.2 Nordic Nanovector Business Overview 100 11.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 100 11.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 100 11.11.5 Nordic Nanovector Business Strategy 101 11.12 Philogen 102 11.12.1 Philogen Company Details 102 11.12.2 Philogen Business Overview 102 11.12.3 Philogen Radioimmunotherapy Products and Services 103 11.12.4 Philogen Radioimmunotherapy SWOT Analysis 103 11.12.5 Philogen Business Strategy 104 11.13 RadioMedix 104 11.13.1 RadioMedix Company Details 104 11.13.2 RadioMedix Business Overview 105 11.13.3 RadioMedix Radioimmunotherapy Products and Services 105 11.13.4 RadioMedix Business Strategy 105 11.14 Telix Pharmaceuticals 106 11.14.1 Telix Pharmaceuticals Company Details 106 11.14.2 Telix Pharmaceuticals Business Overview 107 11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 107 11.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108 11.14.5 Telix Pharmaceuticals Business Strategy 108 11.15 Orano Med 109 11.15.1 Orano Med Company Details 109 11.15.2 Orano Med Business Overview 110 11.15.3 Orano Med Radioimmunotherapy Products and Services 110 11.15.4 Orano Med Radioimmunotherapy SWOT Analysis 110 11.15.5 Orano Med Business Strategy 111 11.16 Actinium Pharmaceuticals 111 11.16.1 Actinium Pharmaceuticals Company Details 111 11.16.2 Actinium Pharmaceuticals Business Overview 112 11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112 11.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113 11.16.5 Actinium Pharmaceuticals Business Strategy 113 11.17 Y-mAbs Therapeutics 114 11.17.1 Y-mAbs Therapeutics Company Details 114 11.17.2 Y-mAbs Therapeutics Business Overview 114 11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115 11.17.4 Y-mAbs Therapeutics Business Strategy 116 11.18 Fusion Pharmaceuticals 116 11.18.1 Fusion Pharmaceuticals Company Details 116 11.18.2 Fusion Pharmaceuticals Business Overview 117 11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117 11.18.4 Fusion Pharmaceuticals Business Strategy 118 12 Radioimmunotherapy Market Dynamics 120 12.1 Radioimmunotherapy Industry Trends 120 12.2 Radioimmunotherapy Market Drivers 121 12.3 Radioimmunotherapy Market Challenges 122 12.4 Radioimmunotherapy Market Restraints 123 13 Research Findings and Conclusion 124 14 Appendix 126 14.1 Research Methodology 126 14.1.1 Methodology/Research Approach 126 14.1.2 Data Source 129 14.2 Author Details 132 14.3 Disclaimer 135
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(competitive analysis)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |